Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Streptavidin（SA） Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R beta

IL-2 R beta

Brief Information

Name:Interleukin-2 receptor alpha chain
Target Synonym:Insulin-Dependent Diabetes Mellitus 10,Interleukin-2 Receptor alpha Subunit,TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,IL2R
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ILB-C52H9 Cynomolgus Cynomolgus IL-2 R beta / CD122 Protein, His Tag (MALS verified)
ILB-C52H9-structure
ILB-C52H9-sds
ILB-M5253 Mouse Mouse IL-2 R beta / CD122 Protein, Fc Tag
ILB-M5253-structure
ILB-M5253-sds
ILA-C52H5 Canine Canine IL-2 R beta Protein, His Tag
ILA-C52H5-structure
ILA-C52H5-sds
ILA-M52H5 Mouse Mouse IL-2 R beta Protein, His Tag
ILA-M52H5-structure
ILA-M52H5-sds
ILB-H82E3 Human Biotinylated Human IL-2 R beta / CD122 Protein, His,Avitag™
ILB-H82E3-structure
ILB-H82E3-sds
ILB-H5253 Human Human IL-2 R beta / CD122 Protein, Fc Tag (MALS & SPR verified)
ILB-H5253-structure
ILB-H5253-sds
CD2-H5221 Human Human IL-2 R beta / CD122 Protein, His Tag (SPR verified)
CD2-H5221-structure
CD2-H5221-sds

Part of Bioactivity data

CD2-H5221-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2 R beta, His Tag (SPR verified) (Cat. No. CD2-H5221) inhibits the IL-15-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.38-0.45 µg/mL (Routinely tested).

Protocol
ILB-M5253-SPR
IL-2 R beta SPR

Mouse IL-2, His Tag (Cat. No. IL2-M52H3) immobilized on CM5 Chip can bind Mouse IL-2 R beta, His Tag (Cat. No. ILA-M52H5) with an affinity constant of 17.6 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
ILA-M52H5-SPR
IL-2 R beta SPR

Mouse IL-2 R beta, His Tag (Cat. No. ILA-M52H5) immobilized on CM5 Chip can bind Mouse IL-2, His Tag (Cat. No. IL2-M52H3) with an affinity constant of 8.45 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

Synonym Name

IL2RB,RP5-1170K4.6,CD122,P70-75

Background

Interleukin-2 receptor (IL-2R) is a heterotrimeric protein expressed on the surface of certain immune cells, such as lymphocytes, that binds and responds to a cytokine called IL-2. The IL-2R is made up of 3 subunits - α (CD25), β (CD122) and γ (CD132) - non-covalently associating. The α and β chains are involved in binding IL-2, while signal transduction following cytokine interaction is carried out by the γ-chain, along with the β subunit. CD122 is also known as IL2R beta, is a member of the type I cytokine receptor family. CD122 is the receptor for interleukin-2 and is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.

Clinical and Translational Updates

Related Molecule

IL-2 IL-15

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis; Rejection of organ transplantation Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis; Rejection of organ transplantation Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Autoimmune Diseases Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Solid tumours Details
RM-1995 RM-1995 Rakuten Medical Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell Details
Camidanlumab tesirine ADCT-301 Genmab, Adc Therapeutics Details
Inolimomab B-B10; BT-563; MAb-BT-563 Eusa Pharma, Jazz Pharmaceuticals Plc Details
RO-7296682 RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
LMB-2 LMB-2; LMB-2a Phase 2 Clinical National Cancer Institute Leukemia; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Lymphoma; Myelodysplastic-Myeloproliferative Diseases Details
PT-101 PT-101; MK-6194 Phase 1 Clinical Pandion Therapeutics Colitis, Ulcerative; Dermatitis, Atopic Details
Nemvaleukin alfa RDB-1450; RDB-1419; ALKS-4230 Phase 3 Clinical Alkermes Plc Solid tumours; Ovarian Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
XmAb-564 XmAb-564; XmAb-27564 Phase 1 Clinical Xencor Autoimmune Diseases Details
In 111-DOTA-Basiliximab Phase 1 Clinical City Of Hope National Medical Center Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
90Y Basiliximab Phase 2 Clinical City Of Hope National Medical Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Solid tumours Details
RM-1995 RM-1995 Rakuten Medical Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Squamous Cell Details
Camidanlumab tesirine ADCT-301 Genmab, Adc Therapeutics Details
Inolimomab B-B10; BT-563; MAb-BT-563 Eusa Pharma, Jazz Pharmaceuticals Plc Details
RO-7296682 RO-7296682; RG-6292 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
LMB-2 LMB-2; LMB-2a Phase 2 Clinical National Cancer Institute Leukemia; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Lymphoma; Myelodysplastic-Myeloproliferative Diseases Details
PT-101 PT-101; MK-6194 Phase 1 Clinical Pandion Therapeutics Colitis, Ulcerative; Dermatitis, Atopic Details
Nemvaleukin alfa RDB-1450; RDB-1419; ALKS-4230 Phase 3 Clinical Alkermes Plc Solid tumours; Ovarian Neoplasms; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap